BLA 103909 · Genentech
Tnkase
Tenecteplase
NovelLast checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jun 2, 2000
Approved uses
2
Original approval plus efficacy supplements
Registered trials
142
88 Phase 3, 49 recruiting
FAERS reports
1,600
1,196 serious, 375 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2025.
TNKase ® is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). TNKase is a tissue plasminogen activator, indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). ( 1 )
Mechanism: Tenecteplase is a modified form of human tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin. In the presence of fibrin, in vitro studies demonstrate that tenecteplase-mediated conversion of plasminogen to plasmin is increased relative to its conversion in the absence of fibrin. This fibrin specificity decreases systemic activation of plasminogen and the resulting degradation of circulating fibrinogen as compared to a molecule lacking this property. The clinical significance of fibrin-specificity on safety (e.g., bleeding) or efficacy has not been...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 28, 2025 Supplement 5197 · Efficacy LabelLetter
- Jun 2, 2000 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
1 products under this application
- TNKASE · TENECTEPLASE 50MG/VIAL · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tenecteplase" as an intervention, any sponsor and status, largest first.
- ACT-GLOBAL Adaptive Platform Trial for StrokePivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06352632 · 20,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 2034
Drug: Standard-dose intravenous tenecteplase; Low-dose intravenous tenecteplase and 9 more · For: Stroke
Sites: Sydney, Australia; Calgary, Canada
Boehringer IngelheimBoehringer Ingelheim
NCT02181985 · 5,989 participants · Start May 2000 · Primary completion Apr 2001
Drug: Full dose TNK-tPA; Half dose TNK-tPA and 3 more · For: Myocardial Infarction
- ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632Pivotal-lookingRecruiting
University of CalgaryAcademic, hospital or other
NCT06320431 · 4,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 30, 2030
Drug: Tenecteplase · For: Acute Ischemic Stroke AIS; Stroke Acute; Stroke, Acute, Stroke Ischemic
Sites: Sydney, Australia; Melbourne, Australia; Calgary, Canada · 24 sites in all
- STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial InfarctionPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00623623 · 1,899 participants · Start Mar 1, 2008 · Primary completion Sep 1, 2012
Drug: enoxaparin; tenecteplase and 1 more · For: Myocardial Infarction
Sites: Salzburg, Austria; Vienna, Austria; Bornem, Belgium · 201 sites in all
- Alteplase-Tenecteplase Trial Evaluation for Stroke ThrombolysisPivotal-lookingCompleted
NHS Greater Glasgow and ClydeAcademic, hospital or other
NCT02814409 · 1,858 participants · Start Dec 15, 2016 · Primary completion Aug 31, 2023
Drug: Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase; Intravenous Tenecteplase · For: Ischemic Stroke
Sites: Glasgow, United Kingdom
Boehringer IngelheimBoehringer Ingelheim
NCT00168792 · 1,671 participants · Start Nov 2003 · Primary completion Jul 2006
Drug: Tenecteplase · For: Myocardial Infarction
Sites: Little Rock, Arkansas; Fort Lauderdale, Florida; St. Petersburg, Florida · 176 sites in all
- Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-Ⅲ)Pivotal-lookingStatus unknown
Beijing Tiantan HospitalAcademic, hospital or other
NCT05745259 · 1,630 participants (planned) · Start Oct 26, 2022 · Primary completion Nov 4, 2023
Drug: Alteplase; Tenecteplase · For: Acute Ischemic Stroke
Sites: Xuancheng, China; Beijing, China; Chongqing, China · 63 sites in all
- A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital SettingPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02181998 · 1,606 participants · Start Jul 2000 · Primary completion Aug 2002
Drug: Full dose tenecteplase; Unfractioned heparin and 1 more · For: Myocardial Infarction
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use412
- no adverse event316
- cerebral haemorrhage162
- angioedema129
- haemorrhage intracranial118
- death81
- haemorrhage81
- drug ineffective72
- cerebrovascular accident71
- haemorrhagic transformation stroke61
- subarachnoid haemorrhage47
- medication error40
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 31 |
| 2006 | 12 |
| 2007 | 25 |
| 2008 | 15 |
| 2009 | 37 |
| 2010 | 14 |
| 2011 | 32 |
| 2012 | 55 |
| 2013 | 56 |
| 2014 | 28 |
| 2015 | 18 |
| 2016 | 16 |
| 2017 | 78 |
| 2018 | 48 |
| 2019 | 44 |
| 2020 | 55 |
| 2021 | 74 |
| 2022 | 101 |
| 2023 | 168 |
| 2024 | 345 |
| 2025 | 177 |
| 2026 | 146 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Tnkase (Tenecteplase) · HCPCS J3101
2024 spending
$30.5M
Beneficiaries
4,258
4,266 claims
Per beneficiary
$7,153
2024 ASP limit $155.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,793,904 |
| 2021 | $7,358,267 |
| 2022 | $13,250,569 |
| 2023 | $23,404,561 |
| 2024 | $30,455,382 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials.
Palaiodimou L, Katsanos AH, Turc G, et al. · Neurology 2024 · Systematic Review, Meta-Analysis
- Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.
Meng X, Li S, Dai H, et al. · JAMA 2024 · Clinical Trial, Phase III, Comparative Study
- Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
Xiong Y, Campbell BCV, Schwamm LH, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Multicenter Study
- Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.
Tao C, Liu T, Cui T, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Fibrinolysis for patients with intermediate-risk pulmonary embolism.
Meyer G, Vicaut E, Danays T, et al. · N Engl J Med 2014 · Comparative Study, Multicenter Study
- Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial.
Ma G, Mo R, Zuo Y, et al. · JAMA 2026 · Clinical Trial, Phase IV, Multicenter Study
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.